Randomised trial comparing low-dose cisplatin and chlorambucil with low-dose cisplatin, chlorambucil, and doxorubicin in advanced ovarian carcinoma
Barker, G.H.; Wiltshaw, E.
Lancet 1(8223): 747-750
1981
ISSN/ISBN: 0140-6736 PMID: 6110955 Document Number: 174173
Patients (98) with advanced ovarian cancer took part in a prospective, randomized trial comparing low-dose cisplatin and chlorambucil with low-dose cisplatin, chlorambucil and doxorubicin. After 4 yr, response rates (> 50%) and proportion of complete remissions (28%) were similar in both groups. Median duration of remission was longest in the complete remitters: 31 mo. in those having cisplatin and chlorambucil and 24 mo. in those having doxorubicin as well.
Document emailed within 1 workday
Related Documents
Jaksić, B.; Brugiatelli, M. 1988: High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL--IGCi CLL-01 trial Nouvelle Revue Francaise d'Hematologie 30(5-6): 437-442Niiya, F.; Ikeda, S.; Nagata, S.; Iwamoto, M.; Shirouzu, K. 2001: A case of advanced gastric cancer complicated with liver metastases responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin, with UFT and low-dose cisplatin for maintenance on an outpatient basis Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(3): 391-394
West, R.J.; Zweig, S.F. 1997: Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide European Journal of Gynaecological Oncology 18(5): 343-348
Murata, K.; Shiraki, K.; Kawakita, T.; Yamamoto, N.; Okano, H.; Nakamura, M.; Sakai, T.; Deguchi, M.; Ohmori, S.; Nakano, T. 2003: Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma Anticancer Research 23(2c): 1719-1722
Portlock, C.S.; Fischer, D.S.; Cadman, E.; Lundberg, W.B.; Levy, A.; Bobrow, S.; Bertino, J.R.; Farber, L. 1987: High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphoma Cancer Treatment Reports 71(11): 1029-1031
Deng, C.; Huang, R.; Lian, L. 1996: Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer Zhonghua Fu Chan Ke Za Zhi 31(3): 159-162
Hua, X.-m.; Ren, X.-w.; Liu, F.-l.; Liu, Y.; Zhang, C.-j.; Li, Z.-j.; Xu, L.; Liu, J.-y.; Liu, Y.-g. 2004: Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC Zhonghua Zhong Liu Za Zhi 26(10): 621-625
Oyama, K.; Hirosawa, H.; Ito, H.; Fukushima, W.; Masutani, H.; Kadoya, N.; Izumi, R.; Hirono, T. 2000: A case of advanced esophageal carcinoma successfully treated with chemoradiation therapy with low-dose cisplatin and 5-fluorouracil Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(6): 899-903
Nakano, K.; Yamamoto, M.; Iwamoto, H.; Hiramoto, T. 2003: Daily low-dose cisplatin plus concurrent high-dose thoracic radiotherapy in elderly patients with locally advanced unresectable non-small-cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(9): 1283-1287
Ardizzoni, A.; Canobbio, L.; Pronzato, P.; Rubagotti, A.; De Palma, M.; Baracco, F.; Serrano, J.; Serrano, S.; Faravelli, B.; Nosenzo, M. 1986: Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung Cancer Treatment Reports 70(7): 891-892
Boven, E.; Tierie, A.H.; Stam, J.; Pinedo, H.M. 1988: Combined radiation therapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer: results of a phase Ii trial Seminars in Oncology 15(6 Suppl 7: 18-19
Sevelda, P.; Dittrich, C.; Salzer, H.; Pateisky, N.; Spona, J. 1986: Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125 Cancer Detection and Prevention 9(5-6): 521-528
Naganuma, A.; Toyoda, M.; Hamada, T.; Hagiwara, S.; Yanagisawa, M.; Kosone, T.; Arai, H.; Abe, T.; Takagi, H. 2007: Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(5): 729-734
Tajima, M.; Ichikawa, W.; Takagi, Y.; Uetake, Y.; Kojima, K.; Osanai, T.; Takenaka, S.; Nihei, Z.; Sugihara, K. 2000: Chemoradiotherapy with low-dose cisplatin and 5-FU for advanced esophageal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(12): 1816-1818
Kobayashi, H. 1985: Cisplatin and ovarian carcinoma--early detection of cisplatin-induced nephrotoxicity Nihon Sanka Fujinka Gakkai Zasshi 37(6): 888-896
Pispirigos, K.; Paradelis, A.G.; Karakiulakis, G. 1997: Evaluation of cardiac subacute toxicity of epirubicin, chlorambucil, cisplatin, methotrexate and a homo-aza-steroid ester with antitumor activity in rats using serum biochemical parameters Arzneimittel-Forschung 47(1): 92-96
Kamata, T.; Hayashi, Y.; Minatoya, G.; Michiwa, Y.; Onishi, I.; Takeda, T.; Koyasaki, N.; Kanno, M. 2001: A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(10): 1419-1422
Schmoll, H.J.; Bokemeyer, C.; Harstrick, A.; Illiger, H.J.; Metzner, B.; Ruther, U.; Osternamm, A.; Preiss, J.; Wilke, H.; Hohnloser, J. 1992: Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors Pathologie-Biologie 39(9): 961
Pasmantier, M.W.; Coleman, M.; Silver, R.T.; Ballard, W.P. 1985: Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens Cancer Treatment Reports 69(6): 689-693
Takamura, H.; Sasaki, S.; Hasebe, K.; Urade, M.; Yagi, M. 2002: A trial of continuous and biweekly low-dose cisplatin and 5-FU with UFT chemotherapy for esophageal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(10): 1809-1815